Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial | Cancer Biomarkers | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.234.102. Please contact the publisher to request reinstatement.
1.
Catalona WJ, Richie JP, Ahmann FR.  et al.  Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.  J Urol.1994;151:1283-1290.Google Scholar
2.
Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.  Eur J Biochem.1990;194:755-763.Google Scholar
3.
Lilja H, Christensson A, Dahlen U.  et al.  Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin.  Clin Chem.1991;37:1618-1625.Google Scholar
4.
Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.  Cancer Res.1991;51:222-226.Google Scholar
5.
Christensson A, Bjork T, Nilsson O.  et al.  Serum prostate-specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer.  J Urol.1993;150:100-105.Google Scholar
6.
Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, Catalona WJ. Correlation of percent free PSA and pathologic features of prostatic carcinomas.  J Urol.1996;155(suppl):415.Google Scholar
7.
Carter HB, Partin AW, Luderer AA.  et al.  Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis.  Urology.1997;49:379-384.Google Scholar
8.
Arcangeli CG, Humphrey PA, Smith DS.  et al.  Percentage of free serum prostate-specific antigen as a predictor of pathological features of prostate cancer in a screening population.  Urology.1998;51:558-564.Google Scholar
9.
Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free PSA for staging of men with clinically localized prostate cancer.  J Urol.1998;159:1238-1242.Google Scholar
10.
Catalona WJ, Smith DS, Wolfert RL.  et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.  JAMA.1995;274:1214-1220.Google Scholar
11.
Partin AW, Catalona WJ, Southwick PC, Subong ENP, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.  Urology.1996;48(suppl):55-61.Google Scholar
12.
Luderer AA, Chen Y, Soriano TF.  et al.  Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.  Urology.1995;46:187-194.Google Scholar
13.
Vashi AR, Wojno KJ, Henricks W.  et al.  Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.  Urology.1997;49:19-27.Google Scholar
14.
Elgamal AA, Cornillie FJ, Van Poppel HP, Van de Voorde WM, McCabe R, Baert LV. Free-to-total prostate-specific antigen ratio as a single test for detection of significant stage T1c prostate cancer.  J Urol.1996;156:1042-1049.Google Scholar
15.
Van Cangh PJ, De Nayer P, Sauvage P.  et al.  Free-to-total prostate-specific antigen (PSA) ratio is superior to total PSA in differentiating benign prostate hypertrophy from prostate cancer.  Prostate Suppl.1996;7(suppl):30-34.Google Scholar
16.
Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer.  Urology.1996;47:518-524.Google Scholar
17.
Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.  J Urol.1998;159:5-12.Google Scholar
18.
Woodrum D, French C, Shamel LB. Stability of free PSA in serum samples under a variety of sample collection and sample storage conditions.  Urology.1996;48(suppl):33-39.Google Scholar
19.
Woodrum DL, French CF, Hill TM.  et al.  Analytical performance of the Tandem®-R free PSA immuno-assay measuring free prostate-specific antigen.  Clin Chem.1997;43:1203-1208.Google Scholar
20.
Hosmer DW, Lemeshow S. Applied Logistic Regression.  New York, NY: John Wiley & Sons Inc; 1989.
21.
Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate-specific antigen values.  J Urol.1994;151:1571-1574.Google Scholar
22.
Efron B. The Jackknife, the Bootstrap, and Other Resampling Plans.  Philadelphia, Pa: Society for Industrial and Applied Mathematics; 1982.
23.
Efron B. Better bootstrap confidence intervals.  J Am Stat Assoc.1993;82:171-185.Google Scholar
24.
Littrup PJ, Goodman AC. Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction.  Cancer.1995;75(suppl):1987-1993.Google Scholar
25.
Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen.  JAMA.1996;276:1309-1315.Google Scholar
26.
Hoeksema MJ, Law C. Cancer mortality rates fall: a turning point for the nation.  J Natl Cancer Inst.1996;88:1706-1707.Google Scholar
27.
Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements.  JAMA.1997;277:1452-1455.Google Scholar
28.
Van Cangh PJ, De Nayer P, de Vischer L.  et al.  Free-to-total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.  Urology.1996;48(suppl):67-70.Google Scholar
29.
Oesterling JE, Jacobsen SJ, Klee GG.  et al.  Free, complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.  J Urol.1995;154:1090-1095.Google Scholar
30.
Pearson JD, Partin AW, Chan DW, Luderer AA, Carter HB. Serial measurements of serum total PSA, free PSA, and free/total PSA ratio in men with and without prostate disease.  J Urol.1996;155(suppl):606.Google Scholar
31.
Carter HB, Pearson JD, Metter JE.  et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.  JAMA.1992;267:2215-2220.Google Scholar
32.
Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.  JAMA.1995;273:289-294.Google Scholar
33.
Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.  J Urol.1997;157:544-547.Google Scholar
34.
Lerner SE, Jacobsen SJ, Lilja H.  et al.  Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.  Urology.1996;48:240-248.Google Scholar
35.
Chan DW, Sokoll LJ, Jones KA, Kelley CA, Subong ENP, Partin AW. Clinical evaluation of two free PSA assays in combination with different total PSA assays.  J Urol.1997;157(suppl):112.Google Scholar
36.
Fortunato A, Dorizzi RM, Marchi G, Cocco C, Davini A. fPSA/tPSA ratios obtained using nine commercial assays.  Clin Chem.1996;42(suppl):268.Google Scholar
37.
Jung K, Stephan C, Lein M.  et al.  Analytical performance and clinical validity of two free prostate-specific antigen assays compared.  Clin Chem.1996;42:1026-1033.Google Scholar
Original Contribution
May 20, 1998

Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial

Author Affiliations

From the Division of Urologic Surgery, Washington University School of Medicine, St Louis, Mo (Dr Catalona); Department of Urology, The Johns Hopkins Hospital, Baltimore, Md (Drs Partin and Walsh and Mr Subong); Baylor College of Medicine, Houston, Tex (Drs Slawin and Scardino); University of Washington, Seattle (Drs Brawer and Lange); Loyola University Medical Center, Maywood, Ill (Dr Flanigan); School of Medicine, University of California at Los Angeles, (Drs Patel and deKernion); Harvard Program in Urology, Brigham and Women's Hospital, Boston, Mass (Dr Richie); Department of Research and Development, Hybritech Inc, San Diego, Calif (Mr Parson, Mss Gasior and Loveland, and Dr Southwick).

JAMA. 1998;279(19):1542-1547. doi:10.1001/jama.279.19.1542
Abstract

Context.— The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use.

Objective.— To develop risk assessment guidelines and a cutoff value for defining abnormal percentage of free PSA in a population of men to whom the test would be applied.

Design.— Prospective blinded study using the Tandem PSA and free PSA assays (Hybritech Inc, San Diego, Calif).

Setting.— Seven nationwide university medical centers.

Participants.— A total of 773 men (379 with prostate cancer, 394 with benign prostatic disease) 50 to 75 years of age with a palpably benign prostate gland, PSA level of 4.0 to 10.0 ng/mL, and histologically confirmed diagnosis.

Main Outcome Measures.— A percentage of free PSA cutoff that maintained 95% sensitivity for prostate cancer detection, and probability of cancer for individual patients.

Results.— The percentage of free PSA may be used in 2 ways: as a single cutoff (ie, perform a biopsy for all patients at or below a cutoff of 25% free PSA) or as an individual patient risk assessment (ie, base biopsy decisions on each patient's risk of cancer). The 25% free PSA cutoff detected 95% of cancers while avoiding 20% of unnecessary biopsies. The cancers associated with greater than 25% free PSA were more prevalent in older patients, and generally were less threatening in terms of tumor grade and volume. For individual patients, a lower percentage of free PSA was associated with a higher risk of cancer (range, 8%-56%). In the multivariate model used, the percentage of free PSA was an independent predictor of prostate cancer (odds ratio [OR], 3.2; 95% confidence interval [CI], 2.5-4.1; P<.001) and contributed significantly more than age (OR, 1.2; 95% CI, 0.92-1.55) or total PSA level (OR, 1.0; 95% CI, 0.92-1.11) in this cohort of subjects with total PSA values between 4.0 and 10.0 ng/mL.

Conclusions.— Use of the percentage of free PSA can reduce unnecessary biopsies in patients undergoing evaluation for prostate cancer, with a minimal loss in sensitivity in detecting cancer. A cutoff of 25% or less free PSA is recommended for patients with PSA values between 4.0 and 10.0 ng/mL and a palpably benign gland, regardless of patient age or prostate size. To our knowledge, this study is the largest series to date evaluating the percentage of free PSA in a population representative of patients in whom the test would be used in clinical practice.

×